Summary
Boston Scientific Corporation (BSX) filed an 8-K on February 10, 2010, detailing its fourth quarter and full-year 2009 financial results and providing initial guidance for 2010. The company also announced significant restructuring initiatives and management changes aimed at enhancing operational efficiency and long-term growth. These restructuring efforts are expected to yield substantial annual pre-tax operating expense reductions once fully implemented by 2011. The restructuring plan, approved by the Board of Directors on February 6, 2010, involves integrating the Cardiovascular and Cardiac Rhythm Management (CRM) businesses, centralizing R&D, and streamlining other business units and corporate functions. This plan anticipates the elimination of 1,000 to 1,300 positions and is estimated to incur pre-tax charges between $180 million and $200 million, with a significant portion expected in 2010. These charges will cover termination benefits, asset write-offs, and other restructuring-related expenses.
Key Highlights
- 1Boston Scientific announced its Q4 and Full Year 2009 financial results and provided initial 2010 guidance.
- 2A significant restructuring plan, the '2010 Plan', was approved on February 6, 2010.
- 3The 2010 Plan aims to reduce annual pre-tax operating expenses by $200 million to $250 million once completed in 2011.
- 4The restructuring involves integrating Cardiovascular and CRM businesses, centralizing R&D, and other organizational changes.
- 5Approximately 1,000 to 1,300 positions are expected to be eliminated.
- 6Total pre-tax charges for the restructuring are estimated between $180 million and $200 million, with $140-160 million expected in 2010.
- 7Key management promotions (Leno, Capello, Colen) and one executive departure (McFaul) were announced as part of the restructuring.